Carlsmed (CARL) investor relations material

Company introduction and technology platform

• Focuses on improving clinical outcomes and reducing healthcare costs in spine surgery using a digital platform and 3D-printed, AI-enabled personalized devices.

• Expanded from lumbar to cervical spine surgery, with recent first-in-human procedures for new personalized fixation products.

Key growth drivers and operational improvements

• Raised over $100 million in IPO, enabling reinvestment in operational excellence, commercial execution, education, and clinical data.

• Reduced turnaround time for device delivery from eight weeks to six days, enhancing integration into surgical practices.

• Broadened ecosystem to include short construct and minimally invasive procedures, with new launches expected in Q4 and further adoption anticipated in 2027 and beyond.

Market adoption, clinical outcomes, and reimbursement

• Two-year outcome data shows a 74% reduction in revision rates for lumbar spine fusion, significantly improving patient outcomes and reducing costs.

• Favorable CMS and Medicare rulings and new DRG codes are expected to simplify reimbursement and expand hospital access, especially for inpatient procedures.

• Rapid adoption of the cervical platform, with strong early feedback and predictable alignment outcomes driving deeper utilization.